161 related articles for article (PubMed ID: 34680201)
1. Copy Neutral LOH Affecting the Entire Chromosome 6 Is a Frequent Mechanism of
Garrido MA; Perea F; Vilchez JR; Rodríguez T; Anderson P; Garrido F; Ruiz-Cabello F; Aptsiauri N
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680201
[TBL] [Abstract][Full Text] [Related]
2. HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15.
Garrido MA; Rodriguez T; Zinchenko S; Maleno I; Ruiz-Cabello F; Concha Á; Olea N; Garrido F; Aptsiauri N
Immunogenetics; 2018 Nov; 70(10):647-659. PubMed ID: 30145665
[TBL] [Abstract][Full Text] [Related]
3. Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors.
Maleno I; Aptsiauri N; Cabrera T; Gallego A; Paschen A; López-Nevot MA; Garrido F
Immunogenetics; 2011 Feb; 63(2):65-71. PubMed ID: 21086121
[TBL] [Abstract][Full Text] [Related]
4. Clonal evolution and clinical significance of copy number neutral loss of heterozygosity of chromosome arm 6p in acquired aplastic anemia.
Betensky M; Babushok D; Roth JJ; Mason PJ; Biegel JA; Busse TM; Li Y; Lind C; Papazoglou A; Monos D; Podsakoff G; Bessler M; Olson TS
Cancer Genet; 2016; 209(1-2):1-10. PubMed ID: 26702937
[TBL] [Abstract][Full Text] [Related]
5. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.
del Campo AB; Kyte JA; Carretero J; Zinchencko S; Méndez R; González-Aseguinolaza G; Ruiz-Cabello F; Aamdal S; Gaudernack G; Garrido F; Aptsiauri N
Int J Cancer; 2014 Jan; 134(1):102-13. PubMed ID: 23784959
[TBL] [Abstract][Full Text] [Related]
6. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
7. High level of aneuploidy of chromosome 6 by FISH analysis of head and neck squamous cell carcinoma: limited applicability of LOH analysis to define HLA loss.
Koene GJ; Arts-Hilkes YH; van Dijk AJ; van der Ven KJ; Slootweg PJ; de Weger RA; Tilanus MG
Hum Immunol; 2004 Dec; 65(12):1455-62. PubMed ID: 15603873
[TBL] [Abstract][Full Text] [Related]
8. Loss of heterozygosity at 6p21.3 underlying HLA class I downregulation in gastric cancer.
Wang XC; Zhang JQ; Shen YQ; Miao FQ; Xie W
J Exp Clin Cancer Res; 2006 Mar; 25(1):115-9. PubMed ID: 16761627
[TBL] [Abstract][Full Text] [Related]
9. Loss of heterozygosity at 6p21 underlying [corrected] HLA class I downregulation in Chinese primary esophageal squamous cell carcinomas.
Yang Y; Zhang J; Miao F; Wei J; Shen C; Shen Y; Xie W
Tissue Antigens; 2008 Aug; 72(2):105-14. PubMed ID: 18721270
[TBL] [Abstract][Full Text] [Related]
10. Loss of Human Leukocyte Antigen and Immune Escape in Head and Neck Cancer.
Morris LGT
Laryngoscope; 2024 Jan; 134(1):160-165. PubMed ID: 37249223
[TBL] [Abstract][Full Text] [Related]
11. Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21.
Maleno I; Cabrera CM; Cabrera T; Paco L; López-Nevot MA; Collado A; Ferrón A; Garrido F
Immunogenetics; 2004 Jul; 56(4):244-53. PubMed ID: 15258706
[TBL] [Abstract][Full Text] [Related]
12. HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas.
Feenstra M; Veltkamp M; van Kuik J; Wiertsema S; Slootweg P; van den Tweel J; de Weger R; Tilanus M
Tissue Antigens; 1999 Sep; 54(3):235-45. PubMed ID: 10519360
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity in the HLA class I region in human pancreatic cancer.
Ryschich E; Cebotari O; Fabian OV; Autschbach F; Kleeff J; Friess H; Bierhaus A; Büchler MW; Schmidt J
Tissue Antigens; 2004 Dec; 64(6):696-702. PubMed ID: 15546343
[TBL] [Abstract][Full Text] [Related]
14. Frequency and genetic basis of MHC, beta-2-microglobulin and MEMO-1 loss of heterozygosity in sporadic breast cancer.
McEvoy CR; Seshadri R; Morley AA; Firgaira FA
Tissue Antigens; 2002 Sep; 60(3):235-43. PubMed ID: 12445306
[TBL] [Abstract][Full Text] [Related]
15. Genomic loss of HLA alleles may affect the clinical outcome in low-risk myelodysplastic syndrome patients.
Montes P; Kerick M; Bernal M; Hernández F; Jiménez P; Garrido P; Márquez A; Jurado M; Martin J; Garrido F; Ruiz-Cabello F
Oncotarget; 2018 Dec; 9(97):36929-36944. PubMed ID: 30651926
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide analysis of recurrent copy-number alterations and copy-neutral loss of heterozygosity in head and neck squamous cell carcinoma.
Marescalco MS; Capizzi C; Condorelli DF; Barresi V
J Oral Pathol Med; 2014 Jan; 43(1):20-7. PubMed ID: 23750501
[TBL] [Abstract][Full Text] [Related]
17. Molecular strategies to define HLA haplotype loss in microdissected tumor cells.
Ramal LM; Maleno I; Cabrera T; Collado A; Ferron A; Lopez-Nevot MA; Garrido F
Hum Immunol; 2000 Oct; 61(10):1001-12. PubMed ID: 11082513
[TBL] [Abstract][Full Text] [Related]
18. LOH at 6p21.3 region and HLA class I altered phenotypes in bladder carcinomas.
Maleno I; Romero JM; Cabrera T; Paco L; Aptsiauri N; Cozar JM; Tallada M; López-Nevot MA; Garrido F
Immunogenetics; 2006 Jul; 58(7):503-10. PubMed ID: 16705407
[TBL] [Abstract][Full Text] [Related]
19. Isolation and molecular characterization of spontaneous mutants of lymphoblastoid cells with extended loss of heterozygosity.
de Nooij-van Dalen AG; van Buuren-van Seggelen VH; Mulder A; Gelsthorpe K; Cole J; Lohman PH; Giphart-Gassler M
Mutat Res; 1997 Mar; 374(1):51-62. PubMed ID: 9067415
[TBL] [Abstract][Full Text] [Related]
20. Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events.
Paschen A; Méndez RM; Jimenez P; Sucker A; Ruiz-Cabello F; Song M; Garrido F; Schadendorf D
Int J Cancer; 2003 Mar; 103(6):759-67. PubMed ID: 12516095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
